Salarius Pharmaceuticals Renames to Decoy Therapeutics, Ticker DCOY
Salarius Pharmaceuticals will change its corporate name to Decoy Therapeutics and its common shares will trade on the Nasdaq Capital Market under the ticker symbol DCOY effective as of commencement of trading on January 8. These changes reflect the Company's focus on developing novel peptide-conjugate therapeutics through its proprietary platform that reduces the complexity of drug development and manufacturing. "Changing our corporate name is another step in our transformation to developing the next generation of peptide-conjugate therapeutics, with an initial emphasis on high-priority viral and oncology targets," said Rick Pierce, CEO. "With an AI-enabled discovery engine, a lead antiviral program of interest to global health stakeholders and a tightly focused 2026 plan, we are positioned to advance our first program into the clinic, expand our pipeline and create long-term value for patients and shareholders." These changes do not affect the total number of shares outstanding, shareholders' rights, the CUSIP number or the transfer agent, nor do they impact the Company's operations or leadership, which includes Decoy's senior management team and Salarius' finance team. The Company's priorities for 2026 include: Advancing lead antiviral programs toward regulatory readiness; Expanding discovery and preclinical validation across multiple platforms; Leveraging AI-enabled computational infrastructure to accelerate candidate selection; Pursuing strategic collaborations with big pharma, technology leaders and academic institutions; Strengthening the Company's capital structure and expanding investor visibility.
Get Free Real-Time Notifications for Any Stock
Analyst Views on SLRX
About SLRX
About the author
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
Salarius Pharmaceuticals Adjourns Annual Meeting to December 31 Due to Insufficient Votes
- Annual Meeting Postponed: Salarius Pharmaceuticals' Annual Meeting scheduled for December 19, 2025, was adjourned due to insufficient quorum, as less than 34% of outstanding shares were represented, indicating low shareholder engagement that could affect decision-making efficacy.
- Insufficient Voting Power: At the time of adjournment, only approximately 30% of shares had been voted, failing to meet the legal requirement, which may delay critical company decisions and impact future strategic direction.
- Rescheduled Meeting: The meeting will reconvene on December 31, 2025, at 10:00 a.m. Central Time via live webcast, with shareholders encouraged to vote promptly, aiming to ensure transparency in governance and active shareholder participation.
- Importance of Shareholder Voting: The company underscores the significance of shareholder votes, urging eligible stockholders as of the October 24, 2025 record date to vote online or by phone, ensuring their voices are heard in corporate decision-making.
